RxDoctor Payments Data

Jamison Wyatt, MD

Interventional Cardiology · New Braunfels, TXNPI 1568642361

Payments from drug & device makers

$38,682in general payments, 2019–2025

Across 338 payments — averaging $114.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$13K
  • Trireme Medical LLC$6K
  • AstraZeneca$5K
  • Abbott$5K
  • Boston Scientific$2K
  • Medtronic$2K
  • plus $7K from 37 others

What the payments were for

  • Travel & lodging$2,82811%
  • Food & beverage$11,00642%
  • Education$60%
  • Other$12,66748%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,682 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$676,647
Medicare patients
1,115
Services billed
4,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban143$176,386
CamzyosMavacamten13$97,963
XareltoRivaroxaban76$74,804
BrilintaTicagrelor41$36,300
EntrestoSacubitril/Valsartan34$30,552
FarxigaDapagliflozin Propanediol30$23,732
Repatha SureclickEvolocumab13$18,222
Metoprolol Succinate233$3,938
ClopidogrelClopidogrel Bisulfate225$2,139
Atorvastatin Calcium273$2,009
Rosuvastatin Calcium135$1,640
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide79$1,528
Bumetanide18$1,077
Losartan Potassium80$1,019
Potassium Chloride56$981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$176,386143 claims
E.r. Squibb & Sons, L.L.C.Camzyos$136$97,96313 claims
Johnson & JohnsonXarelto$664$74,80476 claims
AstraZenecaBrilinta, Farxiga$4,941$60,03271 claims
NovartisEntresto$274$30,55234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →